within Pharmacolibrary.Drugs.ATC.B;

model B01AE04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.0020666666666666667,
    adminDuration  = 600,
    adminMass      = 24 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 600,            
    Vdp             = 0.018,
    k12             = 16,
    k21             = 16
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AE04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Melagatran is a direct thrombin inhibitor that was developed as an oral anticoagulant for the prevention and treatment of thromboembolic disorders, such as deep vein thrombosis. It is the active metabolite of ximelagatran. Melagatran was never approved for widespread clinical use due to concerns about hepatotoxicity observed during development.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Gustafsson, D, &amp; Elg, M (2003). The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. <i>Thrombosis research</i> 109 Suppl 1 S9–S15. DOI:<a href=&quot;https://doi.org/10.1016/s0049-3848(03)00249-4&quot;>10.1016/s0049-3848(03)00249-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12818629/&quot;>https://pubmed.ncbi.nlm.nih.gov/12818629</a></p></li><li><p>Fager, G, et al., &amp; Eriksson, UG (2003). Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. <i>European journal of clinical pharmacology</i> 59(4) 283–289. DOI:<a href=&quot;https://doi.org/10.1007/s00228-003-0619-x&quot;>10.1007/s00228-003-0619-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12845508/&quot;>https://pubmed.ncbi.nlm.nih.gov/12845508</a></p></li><li><p>Eriksson, UG, et al., &amp; Eriksson, BI (2003). Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. <i>Clinical pharmacokinetics</i> 42(7) 687–701. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200342070-00006&quot;>10.2165/00003088-200342070-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12844328/&quot;>https://pubmed.ncbi.nlm.nih.gov/12844328</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AE04;
